[Management of bone metastasis originating from lung cancer].
The preceding molecular target therapies have prolonged the life expectancy of many lung cancer patients, and some lung cancer patients have become long-term survivors. On the other hand, the proportion of patients who suffer from complications with bone metastasis and skeletal-related events(SRE)is increasing. Through management of bone metastasis, the preservation of quality of life and functional independence can be better maintained. Zoledronic acid and denosumab are usable in clinical practice; However, there are many problems in regard to treatments for bone metastasis. Lung cancer patients should be treated with bone metastasis with the coordinating cooperation between orthopedists, radiotherapists and dental surgeons.